Nektar Therapeutics Inc. and PureTech Health plc ended talks of a business combination, the companies said Tuesday, because media speculation implied a deal was further along than it was.
Shares of San Francisco-based Nektar closed up Tuesday to $3.555, a mild 6% bump from the middle of last week when whispers of a deal emerged. In that same period, PureTech saw its stock fluctuate from $25.05 last Wednesday to a high of $36.02 Thursday and a low of $23.50 Friday before closing today at $24.01.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Fortune 500 company FIS opens new Jacksonville headquarters in RiversideIn late 2019, FIS committed to bring at least 500 new jobs to Jacksonville within 10 years to increase its local workforce to 1,800 employees. Pozmanter said FIS is already 75% of the way to that goal as of the headquarters opening.
La source: Florida Times-Union - 🏆 600. / 51 Lire la suite »
Stock market news today: Dow and S&P 500 updatesShoppers are pulling back as prices climb higher hello from Iran ,islamic republic has killed a 7 year old girl in Bukan with direct shot pls be our voice they are the most cruel they have killed many peole till now i'm bagging ,pls help us seriousely what else should happen we need help:) مهسا_امینی not just that but they have killed 1girl student(internal bleeding)and arrested 10and injured7 of them I'm talking about school:)can you imagine pls be our voice we need you serious actions against the most cruel regime plss.. مهسا_امینی
La source: CNN - 🏆 4. / 95 Lire la suite »
Nektar, PureTech Health pull plug on merger talks - San Francisco Business TimesNektar cut about 500 jobs and decided to sublease 200,000 square feet in San Francisco after a promising cancer drug failed clinical trials earlier this year.
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »